RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: testing Dupilumab for Atopic Dermatitis

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment.

Official registry: https://clinicaltrials.gov/study/NCT07467564 · Sanofi · enrollment listed as 184

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 184 people at 7 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries

Interventions: Dupilumab

Primary outcome (registry wording): Proportion of Participants with Hospital Anxiety and Depression Scale Anxiety (HADS-A) Sub-scores of Less Than 8

Who it is for (from inclusion criteria)

Ages 12 Years to any
Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression
Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation

Who the registry excludes

Females who are pregnant, lactating, or planning/intending to be pregnant in the next 6 months
Participants who are participating in another trial
Participants with active chronic or acute infection requiring systemic treatment
Participants who are diagnosed with active endoparasite infection or are suspected of being at high risk of infection
Participants with human immunodeficiency virus (HIV), hepatitis B or C, malignancy, or other concomitant illnesses
Participants on antidepressants/anti-anxiety within 6 months of enrolment or those who are planning to receive antidepressants/anti-anxiety. In addition, those who will use antidepressants/anti-anxiety medications throughout the study will be excluded from the analysis
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial

Public study contact (from the registry)

Trial Transparency email recommended (Toll free for US & Canada)

800-633-1610

Contact-US@sanofi.com

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

Investigational Site: Hamad Medical Corporation — Doha, Qatar (active_not_recruiting)
Investigational Site: Saudi Medical Services (Medical Fakeeh) — Jeddah, Saudi Arabia (recruiting)
Investigational Site: King Faisal Specialist Hospital — Jeddah, Saudi Arabia (active_not_recruiting)
Investigational Site: NMC Specialty Hospital LTD — Abu Dhabi, United Arab Emirates (recruiting)
Investigational Site: Dibba Hospital — Fujairah, United Arab Emirates (recruiting)
Investigational Site: Ibrahem Bin Hamad Hospital — Ras al-Khaimah, United Arab Emirates (recruiting)
Investigational Site: Al Qassimi Hospital — Sharjah city, United Arab Emirates (active_not_recruiting)

Related recruiting trials in this snapshot

RecruitingPhase 2Bethesda, Maryland

Phase 2: testing Fluoxetine for Anxiety Disorders

Study Description: This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG).

NCT00018057 · Official ClinicalTrials.gov record · National Institute of Mental Health (NIMH)

RecruitingNot a traditional drug phasePittsburgh, Pennsylvania

Not a traditional drug phase: Blood draw, skin biopsy or urine collection for Cutaneous T-cell Lymphoma

This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

NCT00177268 · Official ClinicalTrials.gov record · University of Pittsburgh

RecruitingNot a traditional drug phaseBethesda, Maryland

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczema.

NCT00605878 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07467564 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07467564?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07467564?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary